Boston Scientific Corporation filings document the regulatory record of a global medical technology company with device and therapy portfolios for cardiovascular, respiratory, digestive, oncological, neurological and urological conditions. Recent 8-K reports furnish operating results, clinical-trial announcements and other material events tied to products such as WATCHMAN and EKOS.
Proxy and governance filings cover director elections, executive compensation, stockholder votes, board committee matters and amendments to the company’s certificate of incorporation. Additional disclosures address capital resources and financing arrangements, including revolving credit terms, along with common-stock reporting, senior debt references, risk-related governance and formal exhibits filed under the Exchange Act.
Michael F. Mahoney reported acquisition or exercise transactions in this Form 4 filing. Boston Scientific Corp. (BSX) reported bona fide gifts of 149,992 and 102,249 common shares on November 4, 2026, by The Michael F. Mahoney Term Irrevocable Trust - 2025 and The Michael F. Mahoney 2 Year Qualified Annuity Trust - 2024, respectively. Both trusts are administered by independent trustees. The report lists Michael F. Mahoney’s holdings on November 4, 2026 as 1,590,024 shares held directly and 22,112 shares through the company’s 401(k) Retirement Savings Plan.
Miriam O'Sullivan, Boston Scientific's SVP, Chief HR Officer, exercised 3,871 restricted stock units on November 1, 2026; each unit represents a commitment to issue one common share. The common-stock transaction lists 3,871 shares acquired, including shares acquired under the Employee Stock Purchase Plan. Separately, 1,872 shares were delivered or withheld for payment of exercise price or tax liability at $41.98 per share. Her post-transaction RSU balance was 0, and 1,731 common shares were held indirectly by her spouse. No Rule 10b5-1 plan is reported.
Boston Scientific Corporation reported third-quarter and nine-month 2026 results. Third-quarter net sales were $5.138 billion versus $5.065 billion a year earlier; net income was $580 million versus $755 million, and diluted earnings per share were $0.40 versus $0.51. For the nine months ended September 30, 2026, net sales were $15.784 billion versus $14.788 billion and net income was $2.823 billion versus $2.222 billion. A $383 million discrete tax benefit affected nine-month tax results.
The company completed the Nalu Medical and Scivita Medical acquisitions. Its TingSN acquisition is expected to close in the fourth quarter of 2026, subject to customary closing conditions; the Penumbra acquisition is expected to close in early 2027, subject to regulatory clearances and other customary closing conditions, after Penumbra stockholders approved it. Boston Scientific paid MiRus $1.500 billion, exclusive of a prior $100 million payment, for non-voting equity interests and an option to acquire its TAVR business for additional aggregate cash payments totaling $3.000 billion following specified clinical and regulatory milestones.
Nine-month operating cash flow was $2.870 billion versus $3.170 billion. The company repurchased $2.000 billion of common stock; $3.000 billion remained under its repurchase authorization as of September 30, 2026.
Boston Scientific Corporation (BSX) reported third-quarter 2026 net sales of $5.138 billion, up 1.5% year over year. GAAP net income attributable to common stockholders was $582 million, or $0.40 per share, versus $755 million, or $0.51, a year earlier; adjusted EPS was $0.73 versus $0.75. For the nine months ended September 30, 2026, net sales were $15.784 billion and net income attributable to common stockholders was $2.830 billion, compared with $14.788 billion and $2.226 billion in 2025.
For full-year 2026, Boston Scientific estimates net sales growth of approximately 4.25% reported and 3.75% organic, with adjusted EPS of $3.16 to $3.18. Its fourth-quarter estimate is for net sales to decline approximately (3.0) to (1.0) percent on reported and organic bases, with adjusted EPS of $0.77 to $0.79.
It received FDA 510(k) clearance for two technologies in the StoneSmart ecosystem and an expanded size offering of the SEISMIQ peripheral lithotripsy catheter. The company commenced enrollment in the Elite AF trial and entered a strategic collaboration with Heartflow on AI-powered CT-guided PCI planning. It noted the American Medical Association's assignment of Category I CPT codes for renal denervation and implantable tibial nerve stimulation devices, effective January 2028.
Boston Scientific Corporation (BSX) announced that Joseph M. Fitzgerald, currently executive vice president and group president, Cardiovascular, will become executive vice president and chief operating officer effective January 1, 2027. On that date, the company will establish three reportable segments—Interventional Therapies, Rhythm Solutions and MedSurg. Fitzgerald will oversee global operations, business units and regions. Interventional Therapies will include the Penumbra business following the anticipated close of the acquisition.
Fitzgerald’s terms include a $1,050,000 annual base salary, an annual bonus target equal to 110% of base salary, and a 2027 equity award with a $7,000,000 grant-date fair value, expected in February 2027 and vesting 25% per year. He may defer up to 75% of the annual bonus awarded for each applicable year. He remains eligible to participate in the Executive Retirement Plan, under which he would be eligible, if he retires as defined by the plan, for a lump-sum payment equal to 2.5 months of base salary for each year of service, subject to a maximum benefit of 36 months. Mark Bickel becomes senior vice president, Global Accounting Controller and chief accounting officer on March 1, 2027; Emily Woodworth (Collins) will then become senior vice president, Global Finance Controller and Finance Transformation.
Boston Scientific Corporation (BSX) said Arthur C. Butcher has decided to retire effective January 1, 2027, from his role as Executive Vice President and Group President, MedSurg and Asia Pacific. He is expected to remain with the company as a senior advisor from that date through February 26, 2027, or an earlier date, which the company defines as the Retirement Date.
As senior advisor, Mr. Butcher will receive his current annual base salary of $780,000, prorated through the Retirement Date. Boston Scientific expects to enter into a Retirement Agreement effective on that date, providing payments and benefits materially consistent with, and subject to the terms of, the Executive Retirement Plan, 2026 Annual Bonus Plan, Long-Term Incentive Program, and related equity awards.
Boston Scientific Corporation (BSX) reports a material cybersecurity incident that caused a global disruption of its information technology systems, temporarily affecting manufacturing and the processing and shipment of customer orders. The company has substantially restored its distribution network, resumed sterilization operations, and restarted manufacturing at most facilities worldwide.
Based on current information, Boston Scientific expects the incident to have a material impact on results for the third quarter and full year 2026 and believes it is unlikely to meet its previously issued net sales growth and adjusted EPS guidance for those periods. The company plans to update its 2026 outlook on October 28, 2026, and does not currently expect a material impact on its long-term financial condition.
BOSTON SCIENTIFIC CORP (BSX) reported that EVP, Global Operations Padraig Andrew O'Connor had 1,171 restricted stock units convert into 1,171 shares of common stock on September 2, 2026. Each unit represents a commitment to issue one Boston Scientific share. Of the shares issued, 567 shares were delivered or withheld to pay the exercise price or tax liability, with the remaining shares held directly. Following the transaction, 3,516 restricted stock units remain outstanding and are scheduled to be settled in four equal annual installments beginning on September 2, 2026. No Rule 10b5-1 trading plan is reported.
BOSTON SCIENTIFIC CORP (BSX) director Susan E. Morano reported purchasing 2,040 shares of common stock on 2026-08-25 in an open-market or private transaction at $49.2195 per share. Following this buy, she directly holds 13,784 shares of Boston Scientific common stock. The Rule 10b5-1 trading plan checkbox was not marked for this transaction.
BOSTON SCIENTIFIC CORP (BSX) reported that on August 25, 2026 it identified a cybersecurity incident affecting certain information technology systems, resulting in a global disruption to its operations. The company activated incident response protocols and engaged third-party cybersecurity experts to investigate and contain the threat.
The incident has caused, and is expected to continue to cause, disruptions and limitations of access to information systems and business applications that support operations, including the ability to process and ship customer orders. Boston Scientific is working to restore affected functions, but the timeline for full restoration is not yet known.
The company states that its investigation is ongoing and that the full scope, nature and impacts, including operational and financial effects, are not yet known. It has not yet determined whether the incident is reasonably likely to have a material impact on the company, and highlights risks such as potential litigation, reputational risk, regulatory scrutiny and possible adverse impacts on business, results of operations or financial condition.